Qlaris Bio, Inc.

9 clinical trials · Sponsor

Record	Firm	Date
Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension (NCT07354516)	Qlaris Bio, Inc.	2026-03-18
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation (NCT07354477)	Qlaris Bio, Inc.	2026-02-20
Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG) (NCT06030193)	Qlaris Bio, Inc.	2025-08-13
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients (NCT06249152)	Qlaris Bio, Inc.	2024-04-21
Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients (NCT06016972)	Qlaris Bio, Inc.	2024-03-05
Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP) (NCT05495269)	Qlaris Bio, Inc.	2022-11-23
A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 (NCT04947124)	Qlaris Bio, Inc.	2021-10-19
A Study to Evaluate Safety and Tolerability of QLS-101 in NTG (NCT04857827)	Qlaris Bio, Inc.	2021-09-15
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension). (NCT04830397)	Qlaris Bio, Inc.	2021-03-31

Every clearance here is in the API, with alerts when new ones post.